Anzeige
Mehr »
Login
Dienstag, 04.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
CES 2025: Wie ein €80M Robotikunternehmen 4 Milliarden Medienimpressionen eroberte!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Stuttgart
04.02.25
10:08 Uhr
3,920 Euro
0,000
0,00 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
4,0704,10012:01

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMedian Technologies: eyonis Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions194Primary endpoint met with statistical significance (p=0.027) in pivotal RELIVE trial of eyonis LCS, Median's AI/ML-based Software as a Medical Device for lung cancer screening eyonis LCS...
► Artikel lesen
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
FrMedian Technologies Reports 2024 Key Financial Indicators and 2025 Outlook223H2 2024 revenue €12.0 million up 10.2% compared to H2 2023 FY 2024 revenue €22.9 million up 3.3% compared to 2023 Growing order backlog at €71.0 million, as of December 31, 2024...
► Artikel lesen
24.01.Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis regulatory filings and commercialization in U.S. and EU312Repayment of 2020 EIB loan to be rescheduled to October 2025 from April New €37.5 million 2025 EIB loan under appraisal, final authorization stage New up to €10 million equity line...
► Artikel lesen
14.01.Median Technologies: Financial Communications Schedule for the First Half of 2025308Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results: Publication Date ...
► Artikel lesen
09.01.Half Year Median Technologies Liquidity Contract Statement209Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following resources were...
► Artikel lesen
08.01.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024184Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
11.12.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024234Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
26.11.24Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis LCS at the Radiological Society of North America (RSNA) 202462Peer-reviewed scientific e-poster: "Performances of an End-to-End AI/ML CADe/CADx SaMD for Nodule Detection and Characterization in Lung Cancer Screening on an Independent Cohort Compared to Radiologists."...
► Artikel lesen
12.11.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024279Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
07.11.24Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis Lung Cancer Screening (LCS) REALITY Data358Two globally leading pulmonologists reviewed REALITY data, AI and the potential impact on lung cancer screening Replay in English is available on the link here A French subtitled...
► Artikel lesen
30.10.24Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening293Webinar to focus on the eyonis Lung Cancer Screening (LCS) REALITY data November 7, 2024 1:30 pm CET 7:30 am ET Registration link Regulatory News: Median Technologies (FR0011049824, ALMDT...
► Artikel lesen
24.10.24Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results345eyonis LCS pivotal REALITY study met all primary and secondary endpoints A webcast including Key Opinion Leaders will be held on November 7, 2024, to discuss the REALITY study results ...
► Artikel lesen
07.10.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30th, 2024286Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
11.09.24Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024479Peer-reviewed scientific poster for eyonis LCS Median iCRO eyonis teams will be at booth #525, Exhibit Hall 3. Regulatory News: Median Technologies FR0011049824, ALMDT, PEA/SME eligible...
► Artikel lesen
06.09.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31st, 2024491Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
04.09.24Median Technologies to share positive pivotal data for eyonis LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer475(San Diego, CA, USA, from September 7-10, 2024) eyonis LCS is a proprietary Software as Medical Device (SaMD) powered by artificial intelligence (AI) machine learning (ML) for early detection...
► Artikel lesen
02.09.24Median Technologies to host two webcasts on September 5, 2024357eyonis LCS: New Horizons in Fighting Lung Cancer" Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company") will host two live webcasts on September...
► Artikel lesen
29.08.24Median Technologies Announces Pivotal REALITY Study of Its eyonis LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints285eyonis LCS met the primary endpoint for accuracy, achieving an Area Under the Curve (AUC)1 of 0.90, significantly above the 0.80 set for regulatory clearance. eyonis LCS met all 9 secondary...
► Artikel lesen
08.08.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31st, 2024275Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
06.08.24Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery370The partnership's aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab's unique AI capabilities. The company is a Top 10...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1